^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Ocrevus (ocrelizumab)
i
Other names: PRO 70769, R 1594, RG1594, rhuMab 2H7, PRO70769, OCR, RO4964913, PRO-70769, R1594, RO-4964913, RG 1594, RO 4964913, R-1594, RG-1594
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Biogen, Roche
Drug class:
CD20 inhibitor
Related drugs:
1d
Effects of Ocrevus in Relapsing Multiple Sclerosis (clinicaltrials.gov)
P4, N=60, Active, not recruiting, Georgia State University | Trial completion date: Apr 2026 --> Sep 2026
Trial completion date
|
Ocrevus (ocrelizumab)
9d
BLOOMS: B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov)
P4, N=296, Active, not recruiting, Amsterdam UMC, location VUmc | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Apr 2024 --> Feb 2027
Enrollment closed • Trial completion date • Trial primary completion date • HEOR
|
Ocrevus (ocrelizumab)
9d
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (clinicaltrials.gov)
P3, N=152, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=444 --> 152
Enrollment closed • Enrollment change
|
Ocrevus (ocrelizumab)
13d
Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap. (PubMed, Clin Pharmacol Ther)
We summarize pivotal translational inflection points, from rituximab extension beyond lymphoma to approvals of ocrelizumab, ofatumumab, ublituximab, and inebilizumab in neuroimmunology. We further review plasma cell-directed and T-cell-engaging strategies for deep immune resets in refractory disease, while clarifying implications for trial design, long-term safety, and implementation. Finally, we introduce a model-informed roadmap integrating population PK/PD, exposure-response, and quantitative systems pharmacology to optimize indication selection, patient enrichment, and dose/regimen design-supporting confident extrapolation rather than empiricism.
Review • Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)
16d
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies (clinicaltrials.gov)
P=N/A, N=1178, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting
Enrollment closed
|
fingolimod • Lemtrada (alemtuzumab) • Ocrevus (ocrelizumab) • Tysabri (natalizumab)
23d
A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus (clinicaltrials.gov)
P1, N=222, Not yet recruiting, Polpharma Biologics International AG
New P1 trial
|
Ocrevus (ocrelizumab)
1m
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations (clinicaltrials.gov)
P1, N=180, Active, not recruiting, R-Pharm
New P1 trial
|
Ocrevus (ocrelizumab)
1m
Mintaka: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (clinicaltrials.gov)
P2, N=360, Recruiting, Hoffmann-La Roche
Trial initiation date
|
Ocrevus (ocrelizumab)
1m
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis (clinicaltrials.gov)
P4, N=50, Recruiting, Johns Hopkins University | Not yet recruiting --> Recruiting
Enrollment open
|
Briumvi (ublituximab-xiiy) • Ocrevus (ocrelizumab)
1m
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients (clinicaltrials.gov)
P=N/A, N=2604, Completed, Novartis Pharmaceuticals
New trial • HEOR • Real-world evidence
|
Ocrevus (ocrelizumab)
2ms
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (clinicaltrials.gov)
P3, N=360, Recruiting, Novartis Pharmaceuticals | N=215 --> 360
Enrollment change • Head-to-Head
|
Rhapsido (remibrutinib) • Ocrevus (ocrelizumab)
2ms
20230309: A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis (2024-512914-16-00)
P2/3, N=375, Active, not recruiting, Amgen Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
Ocrevus (ocrelizumab)
Share via
